Side Effects of ruxolitinib topical: A Synthesis of Findings from 18 Studies

  1. Home
  2. Side Effects of ruxolitinib topical
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of ruxolitinib topical: A Synthesis of Findings from 18 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of ruxolitinib topical: A Synthesis of Findings from 18 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Ruxolitinib topical is a new treatment option for vitiligo, a chronic autoimmune skin disorder that causes loss of skin pigmentation. 2 It is a selective JAK1/2 inhibitor, which means it blocks the activity of certain proteins that are involved in the immune response. 2 This inhibition helps to reduce the inflammation that causes vitiligo. 2 Studies have shown that ruxolitinib topical is effective in treating vitiligo, and it is generally well-tolerated. 2 12

Reasons for Side Effects

Ruxolitinib topical is a JAK inhibitor, and JAKs are involved in various immune processes. By inhibiting these proteins, ruxolitinib can affect the immune system, potentially leading to side effects. 2

Common Side Effects

Infections

Ruxolitinib topical can suppress the immune system, making patients more susceptible to infections. 15 6

Skin Side Effects

Ruxolitinib topical can cause skin side effects such as rash, itching, and dryness. 2

Gastrointestinal Side Effects

Ruxolitinib topical can lead to gastrointestinal side effects like nausea, vomiting, and diarrhea. 1

Other Side Effects

Other side effects of ruxolitinib topical can include headache, dizziness, and fatigue. 15

Side Effects Management

Infections

Maintaining good hygiene practices like hand washing and avoiding contact with sick individuals can help prevent infections. 15 Consulting a doctor promptly if feeling unwell is crucial. 15

Skin Side Effects

If you experience skin side effects, it is important to consult your doctor. 2 They can recommend appropriate treatments for the skin symptoms.

Gastrointestinal Side Effects

If you experience gastrointestinal side effects, consulting your doctor is necessary. 1 They can recommend dietary changes or adjustments to your medication regimen to manage these side effects.

Comparison Between Studies

Commonalities

Multiple studies have shown that ruxolitinib topical can be an effective treatment option for vitiligo. 2 12 16 By inhibiting JAK1/2, ruxolitinib can suppress the immune response and potentially improve vitiligo symptoms. 17 2

Differences

The effectiveness of ruxolitinib topical can vary depending on the individual and their specific disease. 2 The frequency and severity of side effects can also vary between patients. 15

Real-life Application Considerations

Ruxolitinib topical is still a relatively new drug, and more research is needed to fully understand its long-term safety and effectiveness. 15 It is crucial to follow your doctor's instructions when using ruxolitinib topical. 2

Current Research Limitations

Research on ruxolitinib topical is still in its early stages, and long-term safety and efficacy data are limited. 15 6 Further research is also needed to determine the optimal dosage and administration methods for ruxolitinib topical.

Future Research Directions

Long-term safety and efficacy studies on ruxolitinib topical are necessary. 15 Research to determine the ideal dosage and administration methods for ruxolitinib topical is also crucial. 6

Conclusion

Ruxolitinib topical is a promising new treatment option for vitiligo, an autoimmune skin disorder. 2 12 While it is generally well-tolerated, it's important to be aware of potential side effects, such as infections and skin reactions. 2 15 As with any medication, always follow your doctor's instructions for safe and effective use. 2

Literature analysis of 18 papers
Positive Content
17
Neutral Content
0
Negative Content
1
Article Type
1
0
0
11
17
1.

Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer's disease.

Author: GrossbergGeorge, MengXiangyi, OlinJason T

Improved ADLs

Rivastigmine patches and capsules demonstrated significant improvement in activities of daily living (ADLs) in patients with probable Alzheimer's disease (AD) compared to placebo.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

2.

Topical ruxolitinib: A new treatment for vitiligo.

Author: TavolettiG, AvalloneG, ConfortiC, RoccuzzoG, MaroneseC A, MattioliM A, QuaglinoP, ZalaudekI, MarzanoA V, RiberoS, Alberti-ViolettiS

Vitiligo treatment

This review summarizes the current evidence concerning the efficacy and safety of topical ruxolitinib, a JAK1/2 inhibitor, in the treatment of vitiligo. Based on phase III clinical trials, topical ruxolitinib demonstrated promising results in treating non-segmental vitiligo, offering a potential treatment option for patients with this chronic skin disorder.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

4.

New Topical Therapies for Psoriasis.

Author: LéAna Maria, TorresTiago

Psoriasis treatment

This review discusses the emerging topical drugs for the treatment of psoriasis, focusing on tapinarof, roflumilast, and brepocitinib.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

5.

Keratinocytes and immune cells in the epidermis are key drivers of inflammation in hidradenitis suppurativa providing a rationale for novel topical therapies.

Author: SchellStephanie L, CongZhaoyuan, SennettMackenzie L, GettleSamantha L, LongeneckerAmy L, GoldbergStephanie R, KirbyJoslyn S, HelmMatthew F, NelsonAmanda M

Adalimumab for HS
JAK inhibitor promise
Serious JAK inhibitor side effects

Hidradenitis suppurativa (HS) is a debilitating skin disease with limited treatment options. This article discusses the need for research into topical treatments and the role of epidermal keratinocytes in the disease.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

6.

Successful treatment of atopic dermatitis with the JAK1 inhibitor oclacitinib.

Author: HaughIsabel M, WatsonIan T, Alan MenterM

Atopic dermatitis treatment
Adverse side effects
Infections

Atopic dermatitis was successfully treated with the oral JAK1 inhibitor oclacitinib, a veterinary medication. This case report suggests the potential of JAK1 inhibitors for treating severe atopic dermatitis, but further research is needed to confirm its safety and efficacy in humans.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Language : English

7.

The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm.

Author: Renert-YuvalYael, Guttman-YasskyEmma

AA treatment
Adverse effects

This review discusses the current state of alopecia areata (AA) treatment and highlights the lack of FDA-approved therapeutics for extensive cases. The article explores the pathogenesis of AA and the potential of novel therapeutics currently undergoing clinical trials, emphasizing the need for mechanism-targeted drugs to improve treatment options for AA.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

8.

Novel Vehicles For Drug Delivery in Atopic Dermatitis: A Narrative Review.

Author: FarkouhChristopher, AnthonyMichelle, AbdiParsa, SantiagoNatalia, FarkouhMatthew

Improved AD treatment
Steroid side effects

Atopic dermatitis is a common skin condition, and topical corticosteroids are the standard treatment, but they can have side effects. This article discusses the need for new drugs and drug delivery methods to treat atopic dermatitis.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

9.

Current emerging and investigational drugs for the treatment of chronic hand eczema.

Author: ChengJulia, FacherisPaola, UngarBenjamin, Guttman-YasskyEmma

CHE Management

Chronic hand eczema (CHE) is a common condition that can be difficult to treat. This review highlights the need for new systemic treatment options for CHE due to the limited efficacy and side effect profiles of current treatments.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

11.

[Systemic treatment of vitiligo : Balance and current developments].

Author: MeurerM, Ceric-DehdariP

Repigmentation
Vitiligo treatment
Side effects

New systemic treatments for vitiligo, such as the α‑MSH-analogue afamelatonide and Janus kinase (JAK) inhibitors, are under clinical investigation. These treatments hold promise for expanding the range of treatment options for vitiligo.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : German

12.

Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib.

Author: RothsteinBrooke, JoshipuraDeep, SaraiyaAmi, AbdatRana, AshkarHuda, TurkowskiYana, ShethVaneeta, HuangVictor, AuShiu Chung, KachukCourtney, DumontNicole, GottliebAlice B, RosmarinDavid

Repigmentation of vitiligo
Minor adverse events

Topical ruxolitinib 1.5% cream provided significant repigmentation in facial vitiligo. Adverse events were minor, including erythema, hyperpigmentation, and transient acne.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

13.

New drugs under investigation for the treatment of alopecias.

Author: Ocampo-GarzaJorge, GriggsJacob, TostiAntonella

Adverse effects
Limited efficacy
Long treatment terms
Slow hair growth

This abstract highlights the challenges of treating alopecia, including slow hair growth, long treatment durations, limited efficacy, and potential side effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

14.

Recent advances in immunomodulators for atopic dermatitis.

Author: YimHyun J, JeanTiffany, OngPeck Y

Atopic dermatitis treatment
Few side effects
Improved efficacy

Newer immunomodulators, such as dupilumab, ruxolitinib, upadacitinib, and abrocitinib, have transformed the treatment of atopic dermatitis, particularly in patients with moderate-to-severe disease.

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

15.

Modern Interventions for Pediatric Atopic Dermatitis: An Updated Pharmacologic Approach.

Author: KondratukKatherine, NetravaliIlka Arun, Castelo-SoccioLeslie

Pediatric AD treatment
Targeted treatments

This review discusses emerging treatments for pediatric atopic dermatitis (AD), including topical and systemic therapies. The review highlights the significant advances brought by targeted treatments like dupilumab and JAK inhibitors and discusses the potential role of newer therapies in managing challenging AD patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

16.

Ruxolitinib-conjugated gold nanoparticles for topical administration: An alternative for treating alopecia?

Author: BocaSanda, BerceCristian, JurjAncuta, PetrushevBobe, PopLaura, GafencuGrigore-Aristide, SeliceanSonia, MoisoiuVlad, TemianDaiana, MicuWilhelm-Thomas, AstileanSimion, BraicuCornelia, TomuleasaCiprian, Berindan-NeagoeIoana

Minimal systemic side effects
Treat alopecia

This study presents preliminary data regarding the potential use of Ruxolitinib-conjugated gold nanoparticles (GNPs) in dermatological conditions. GNPs conjugated with Ruxolitinib inhibit the proliferation of fibroblasts by inhibiting JAK2 protein.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

17.

Evaluating topical JAK inhibitors as a treatment option for atopic dermatitis.

Author: FardosMohammad I, SinghRohan, PerchePatrick O, KellyKatherine A, FeldmanSteven R

AD treatment
Medication adherence

This review discusses the use of topical JAK inhibitors for treating atopic dermatitis. Topical JAK inhibitors are an emerging alternative to traditional therapies, offering promising efficacy and safety profiles. However, medication adherence may pose a challenge to their clinical use.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

18.

DrugCentral 2023 extends human clinical data and integrates veterinary drugs.

Author: AvramSorin, WilsonThomas B, CurpanRamona, HalipLiliana, BorotaAna, BoraAlina, BologaCristian G, HolmesJayme, KnockelJeffrey, YangJeremy J, OpreaTudor I

Adverse drug event information
Drug information
Off-label use information
Veterinary drug information

This report describes DrugCentral, a database that monitors new drug approvals and standardizes drug information. New additions include veterinary drugs, documented off-label uses, and adverse drug events from pharmacovigilance data for pediatric and geriatric patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.